Llwytho...

非小细胞肺癌EGFR突变的分子影像学在体检测

An ever increasing number of drugs directed as epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) bring a new revolution for non-small cell lung cancer (NSCLC) therapy, and many large scales of studies show that only people with EGFR-sensitive mutation can benefit from these drugs...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Zhongguo Fei Ai Za Zhi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 中国肺癌杂志编辑部 2017
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5973363/
https://ncbi.nlm.nih.gov/pubmed/28641700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.08
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!